
First PIK3CA inhibitor treatment approved, along with diagnostic test.

Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

Vitamin D analog foam indicated for topical treatment of plaque psoriasis in teens.

Deciding which sunscreen to apply has become a complicated business.

Oral solution now approved for adults and pediatric patients.

Update: now available from three manufacturers.

Specialty pharmacy has reached an “inflection point” with the power to change the entire industry model.

Nayzilam is a benzodiazepine antiepileptic nasal spray.

Medical researchers and physicists are collaborating on oral vaccine research.

Both pharmacy groups state that rule should have addressed DIR fees.

Studies indicate a lack of deprescribing is causing physical and fiscal pain to patients.

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pete Kreckel discusses how he is always working to improve the workflow in his pharmacy.

Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.

Approval marks the first anti-PD-L1 therapy combination for RCC.

With tight margins, DIR fees, generic effective rate fees, and the delay in receiving third-party reimbursements, it’s easy to find yourself faced with cash flow pressures.

Suit filed in Connecticut alleges companies conspired to inflate prices on more than 100 generic drugs.

Results from IQVIA Institute for Human Data Science's annual report, "Medicine Use and Spending in the U.S."

Despite legal restrictions and insufficient regulation, the market for CBD oil is booming.

Biosimilar guidance provides “clarity” for drug developers.

New indication joins a series of single-agent and combination treatments for various cancers.

As patient needs place greater demands on PCPs, pharmacy is changing - and it means opportunities for new lines of service.

The company is donating enough drugs for 200,000 patients for up to 11 years, but does it make up for the high price of the drug?

A look at common HIPAA mistakes in pharmacies and how to avoid them.

Brian McCullough, PharmD, BCPS, of Husson University notes some common mistakes pharmacists make with patient privacy and offers some ways to fix them.
